FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim ef
Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim ef